An interventional study of Verbal Summary and Written Summary in Alzheimer Dementia (AD) and Mild Cognitive Impairment (MCI) Amnestic, sponsored by New York University. Not yet recruiting at 1 site in United States. Open to participants aged 65 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by New York University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 529th largest by planned enrollment of the 1,611 interventional ones that give a count, is one of 9 that started in 2027, is one of 611 with no phase, reaches primary completion later than 426 of the 446 other live ones, and was the 1,942nd registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 65 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,942 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 9 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,611 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,942 have an industry lead sponsor. The 10 most frequent:
New York University is the lead sponsor of 124 studies on the registry; 33 are open to participants now.
New York University has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
166 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 166 to your calendar (.ics) → With an account.
Among the 1,942 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study examines how conversational engagement and different forms of communication support affect memory in older adults with and without mild cognitive impairment (MCI) or mild Alzheimer's disease (AD). Participants will complete conversational and memory tasks, including simulated health-related conversations, across five study visits. The study will compare how actively generating information during conversation and receiving verbal or written communication support influence immediate and delayed memory. It will also examine how individual differences in cognitive abilities and visual attention are associated with memory for information exchanged during conversation. Findings from this study may help identify communication strategies that support everyday memory and communication in older adults experiencing cognitive decline.
Effective everyday communication requires individuals not only to understand information provided by others but also to actively contribute to and remember information exchanged during conversation. Active participation in conversation may enhance subsequent memory because generating information can produce stronger memory representations than passively receiving the same information. However, little is known about whether this generation benefit is preserved in cognitive aging and Alzheimer's disease and related dementias (AD/ADRD).
This study will investigate the cognitive and communicative mechanisms that support memory for information exchanged during conversation in older adults with healthy cognition and those with mild cognitive impairment (MCI) or mild Alzheimer's disease (AD). The study will examine whether information that participants actively generate during conversation is better remembered than information they receive from a conversational partner and whether communication supports, including verbal and written support, influence subsequent memory for conversational information.
The study will also investigate individual differences that may contribute to successful memory during communication. Cognitive and language measures and visual attention during conversational tasks will be examined as potential predictors of memory performance. By identifying mechanisms and communication conditions that support memory for conversational information, this research aims to improve understanding of everyday communication and memory across cognitive aging and early-stage cognitive impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the three communication-support conditions in the following counterbalanced order: verbal summary, no summary, and written summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.
Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary
Participants receive the three communication-support conditions in the following counterbalanced order: written summary, no summary, and verbal summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.
Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary
Participants receive the three communication-support conditions in the following counterbalanced order: no summary, verbal summary, and written summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.
Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary
Participants receive the three communication-support conditions in the following counterbalanced order: no summary, written summary, and verbal summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.
Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary
Participants receive the three communication-support conditions in the following counterbalanced order: verbal summary, written summary, and no summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.
Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary
Participants receive the three communication-support conditions in the following counterbalanced order: written summary, verbal summary, and no summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.
Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary
Participants complete a simulated health-related conversation and are given an opportunity to summarize the content of the conversation in their own words verbally. This condition is designed to examine whether actively generating a verbal summary of information exchanged during conversation supports subsequent memory for the conversation content.
Participants complete a simulated health-related conversation and are given an opportunity to summarize the content of the conversation in their own words in writing. This condition is designed to examine whether actively generating a written summary of information exchanged during conversation supports subsequent memory for the conversation content.
Participants complete a simulated health-related conversation without an opportunity to, verbally or in writing, summarize the conversation content. This condition serves as the comparison condition for examining the effects of verbal and written summarization on subsequent memory for information exchanged during conversation.
proportion of correctly recalled information units during conversation tasks
Conversational memory performance will be measured as the proportion of correctly recalled information units (IUs) from structured and unstructured conversational tasks. An IU is a discrete, meaningful component of information presented during a conversation. Recall performance will be calculated by dividing the number of correctly recalled IUs by the total number of eligible IUs. Scores range from 0 to 1, with higher scores indicating better memory performance. Performance will be compared across speaking and listening conditions, across memory support strategies, and between healthy older adults and individuals with mild cognitive impairment or mild Alzheimer's disease.
Time frame: across five weekly study visits
visual attention during conversation tasks
Eye-tracking measures will be used to examine visual attention during conversational tasks. Gaze patterns, including fixation duration and allocation of visual attention to predefined areas of interest (e.g., faces and objects), will be analyzed to investigate relationships between attentional engagement, conversational conditions, cognitive status, and subsequent memory performance.
Time frame: during eye-tracking conversational tasks
Plan to share: Yes
Supporting information: Study protocol, Analytic code
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for May 2031, 52 months later.
Of 885 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 52 months is above that.
Counting every sponsor, half of 962 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.